PO.MCB06.04 · 分子与细胞生物学
利用用于染色质状态和遗传变异的新型多组学长读长测序工具解析基因组调控复杂性
Resolving genome regulatory complexity with new multiomic long-read sequencing tools for chromatin state and genetic variation
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
高分辨率的表观基因组洞察对于指导癌症研究中生物标志物和机制的发现至关重要。现代短读长测序(SRS)方法,如ATAC-seq、WGBS和CUT&RUN/ChIP-seq,一直是研究染色质结构的主力,但它们存在根本性的局限。这些方法缺乏多组学洞察,需要费力、昂贵且消耗样本的平行检测。此外,这些检测会将DNA片段化,丢失关于协同调控效应的关键信息,并且对基因组中重复和结构复杂的区域视而不见。这些局限性制约了理解基因调控以及将遗传发现转化为临床洞察的进展。为克服这些局限,EpiCypher正在开发多组学长读长测序(LRS)技术,以实现单分子表观基因组图谱分析。这些方法将染色质特征直接记录到天然DNA上,在单个DNA分子间保留染色质状态与遗传变异之间的内在关系。Fiber-seq采用N6-腺嘌呤(6mA)甲基转移酶(Hia5)将染色质可及性直接记录到DNA上,同时保留内源性DNA甲基化(5mC)。我们已简化了Hia5的制备和标记工作流程,实现了近碱基对分辨率的稳健单分子染色质可及性图谱分析,在实验台上易于采用。Fiber-seq揭示了精确的转录因子(TF)结合足迹和顺式调控单倍型,如在一项遗传疾病诊断中所示(PMID: 40166185),凸显了其在疾病变异-功能发现方面的潜力。DAF-seq(脱氨酶辅助单分子染色质纤维测序)通过使用双链DNA胞嘧啶脱氨酶(SsDddA)将染色质可及性编码为在PCR扩增过程中维持的突变,从而补充了这一方法。因此,DAF-seq可以从低输入量甚至单细胞中提供高分辨率的染色质图谱和TF足迹(bioRxiv DOI: 10.1101/2024.11.06.622310)。值得注意的是,与领先的单细胞ATAC-seq技术相比,DAF-seq的基因组覆盖率提高了近7,000倍,同时成本仅为其一小部分。Fiber-seq和DAF-seq共同构成了一个多功能工具包:Fiber-seq提供无偏倚的多组学发现,可同时评估全基因组范围内的染色质可及性、DNA甲基化和推断的TF结合;而DAF-seq则能够从低输入量样本进行靶向染色质可及性图谱分析,在单分子分辨率下解析异质性。这些LRS技术在单分子上桥接遗传和染色质调控信息,以揭示疾病机制、定义药物反应并推动精准医学。
查看英文原文 English abstract
High-resolution epigenomic insights are vital to inform the discovery of biomarkers and mechanisms in cancer research. Modern short-read sequencing (SRS) methods such as ATAC-seq, WGBS, and CUT&RUN/ChIP-seq have served as workhorses for studying chromatin architecture, but they are fundamentally limited. These methods lack multiomic insights, requiring labor-intensitve, costly, and sample-consuming parallel assays. Moreover, these assays fragment DNA, losing critical information about coordinated regulatory effects, and are blind to repetitive and structurally complex regions of the genome. These limitations constrain progress in understanding gene regulation and translating genetic discoveries into clinical insights. To overcome these limitations, EpiCypher is developing multiomic long-read sequencing (LRS) technologies that enable single-molecule epigenomic profiling. These approaches directly record chromatin features onto native DNA, preserving the intrinsic relationships between chromatin states and genetic variation across individual DNA molecules. Fiber-seq employs an N6-adenine (6mA) methyltransferase (Hia5) to record chromatin accessibility directly onto DNA, while retaining endogenous DNA methylation (5mC). We have streamlined Hia5 manufacturing and labeling workflows, enabling robust single-molecule chromatin accessibility profiling with near base-pair resolution, readily adopted at the bench. Fiber-seq reveals precise transcription factor (TF) binding footprints and cis-regulatory haplotypes as demonstrated in a genetic disease diagnosis (PMID: 40166185), highlighting its potential for variant-to-function discovery in diseases. DAF-seq ( D eaminase- A ssisted single-molecule chromatin F iber seq uencing), complements this approach by using a dsDNA cytosine deaminase (SsDddA) to encode chromatin accessibility as a mutation maintained through PCR amplification. As a result, DAF-seq can deliver high-resolution chromatin profiles and TF footprints from low-inputs or even single-cells (bioRxiv DOI: 10.1101/2024.11.06.622310). Remarkably, DAF-seq delivers nearly a 7,000-fold improvement in genome coverage compared to leading single-cell ATAC-seq technologies, while operating at a fraction of the cost.Together, Fiber-seq and DAF-seq represent a versatile toolkit: Fiber-seq provides an unbiased multiomic discovery to simultaneously assess chromatin accessibility, DNA methylation, and inferred TF binding genome-wide; while DAF-seq enables targeted chromatin accessibility mapping from low-input samples, resolving heterogeneity at single-molecule resolution. These LRS technologies bridge genetic and chromatin regulatory information on single molecules to reveal disease mechanisms, define drug responses, and drive precision medicine.
利益披露 Disclosure
L. Sun, None..
J. T. Anderson, None..
C. P. Frasier, None..
A. R. Hickman, None..
S. R. Hunt, None..
E. A. Madden, None..
K. E. Maier, None..
A. L. Johnstone, None..
Z. Sun, None..
M. W. Cowles, None..
A. B. Stergachis, None..
B. J. Venters, None..
M. Keogh, None.